Claudia Trenkwalder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Claudia Trenkwalder has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Andrew John Lees
The National Hospital, Queen Square and Reta Lila Weston Institute for Neurological Studies University College London, United Kingdom
1 shared publication Barbara Schormair
Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany
1 shared publication- Birgit Högl
Neurology Department, Sleep Disorders Clinic Innsbruck Medical University Innsbruck Austria
1 shared publication Brit Mollenhauer
Paracelsus-Elena-Klinik, Kassel, Germany; Department of Neurology, University Medical Center Goettingen, Goettingen, Germany
1 shared publicationDonna Lockhart
Britannia Pharmaceuticals Limited, Reading, UK
1 shared publication- Friederike Sixel-Döring
Paracelsus-Elena-Klinik and Philipps University
1 shared publication
Latest Publications
- 24 September 2021
- Published by Springer Nature in InFo Neurologie + Psychiatrie
- Vol. 23 (9) , 40-49
Parkinson-Therapie in der Pandemie
- 24 September 2021
- Published by Springer Nature in InFo Neurologie + Psychiatrie
- Vol. 23 (9) , 40-49
Parkinson-Therapie in der Pandemie
- Open Access
- 1 February 2021
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 83, 79-85
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
- 1 February 2021
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 83, 79-85
Open AccessLong-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
- 1 January 2020
- Published by Elsevier in The Lancet Neurology
- Vol. 19 (1) , 10-12
Movement disorders in 2019: from antibodies to lifestyle interventions
- 1 January 2020
- Published by Elsevier in The Lancet Neurology
- Vol. 19 (1) , 10-12
Movement disorders in 2019: from antibodies to lifestyle interventions
- Open Access
- 26 March 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (13) , e1487-e1496
Increased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial
Objective To investigate whether increased fixed carbidopa doses of 65 or 105 mg (ODM-101/65 and ODM-101/105) in combination with 75, 100, 125, or 150 mg of levodopa and 200 mg of entacapone might improve “off” time in fluctuating Parkinson disease (PD) compared to the standard combination of 4:1 levodopa/carbidopa with the usual 200 mg of entacapone (LCE) during a 4-week treatment period. Methods This was a randomized, double-blind, double-dummy, active-controlled, crossover, multicenter, phase II, proof-of-concept study in patients with fluctuating PD. Results One hundred seventeen patients were randomized into the study (mean age 67.0 years; daily “off” time 5.3 hours; mean daily levodopa dose 610 mg). Carryover-adjusted mean changes from baseline “off” times were during ODM-101/65, −1.53 hours (p = 0.02 vs LCE), during ODM-101/105, −1.57 hours (p = 0.01 vs LCE), and during LCE −0.91 hours. Changes in daily “on” time without dyskinesia were 1.54 hours (p = 0.005 vs LCE), 1.38 hours (p = 0.0214 vs LCE), and 0.69 hours, respectively. Changes in “on” time with troublesome dyskinesia were p = 0.015 and p = 0.006). No difference between the treatments was seen in safety and tolerability. The most common treatment-related adverse effects were nausea, dizziness, drug-effect decrease, and dyskinesia, which were in most cases mild or moderate in severity. Treatment-related serious adverse events were diarrhea (ODM-101/105 and LCE), and myocardial ischemia and blood creatine kinase increase (LCE). Conclusion Increasing the dose of carbidopa in combination with levodopa and entacapone should be considered in the treatment of fluctuating PD to improve daily “off” times. Genotyping patients with PD according to COMT activity may improve individual treatment strategies. ClinicalTrials.gov identifier NCT01766258. Classification of evidence This study provides Class II evidence that an increased dose of carbidopa improves motor fluctuations when administered with levodopa and entacapone.
- 26 March 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (13) , e1487-e1496
Open AccessIncreased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial
Objective To investigate whether increased fixed carbidopa doses of 65 or 105 mg (ODM-101/65 and ODM-101/105) in combination with 75, 100, 125, or 150 mg of levodopa and 200 mg of entacapone might improve “off” time in fluctuating Parkinson disease (PD) compared to the standard combination of 4:1 levodopa/carbidopa with the usual 200 mg of entacapone (LCE) during a 4-week treatment period. Methods This was a randomized, double-blind, double-dummy, active-controlled, crossover, multicenter, phase II, proof-of-concept study in patients with fluctuating PD. Results One hundred seventeen patients were randomized into the study (mean age 67.0 years; daily “off” time 5.3 hours; mean daily levodopa dose 610 mg). Carryover-adjusted mean changes from baseline “off” times were during ODM-101/65, −1.53 hours (p = 0.02 vs LCE), during ODM-101/105, −1.57 hours (p = 0.01 vs LCE), and during LCE −0.91 hours. Changes in daily “on” time without dyskinesia were 1.54 hours (p = 0.005 vs LCE), 1.38 hours (p = 0.0214 vs LCE), and 0.69 hours, respectively. Changes in “on” time with troublesome dyskinesia were p = 0.015 and p = 0.006). No difference between the treatments was seen in safety and tolerability. The most common treatment-related adverse effects were nausea, dizziness, drug-effect decrease, and dyskinesia, which were in most cases mild or moderate in severity. Treatment-related serious adverse events were diarrhea (ODM-101/105 and LCE), and myocardial ischemia and blood creatine kinase increase (LCE). Conclusion Increasing the dose of carbidopa in combination with levodopa and entacapone should be considered in the treatment of fluctuating PD to improve daily “off” times. Genotyping patients with PD according to COMT activity may improve individual treatment strategies. ClinicalTrials.gov identifier NCT01766258. Classification of evidence This study provides Class II evidence that an increased dose of carbidopa improves motor fluctuations when administered with levodopa and entacapone.
- 20 March 2019
- Published by Elsevier
- Vol. 84, 255-265
Pharmacological treatments of augmentation in RLS patients
- 20 March 2019
- Published by Elsevier
- Vol. 84, 255-265
Pharmacological treatments of augmentation in RLS patients
- Top Cited Papers
- 1 November 2018
- Published by Elsevier in The Lancet Neurology
- Vol. 17 (11) , 994-1005
Comorbidities, treatment, and pathophysiology in restless legs syndrome
- 1 November 2018
- Published by Elsevier in The Lancet Neurology
- Vol. 17 (11) , 994-1005
Top Cited PapersComorbidities, treatment, and pathophysiology in restless legs syndrome